Clinical Trials Logo

Neuroendocrine Tumours clinical trials

View clinical trials related to Neuroendocrine Tumours.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04579679 Active, not recruiting - Clinical trials for Neuroendocrine Tumours

Open-Label Surufatinib in European Patients With NET

Start date: August 13, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).

NCT ID: NCT02923934 Active, not recruiting - Clinical trials for Gastrointestinal Cancer

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Start date: August 22, 2017
Phase: Phase 2
Study type: Interventional

The three tumour streams that will be studied in this protocol are: (i) upper GI malignancies (comprising intra-hepatic/extra-hepatic cholangiocarcinomas,gall bladder cancers and duodenal cancers).); (ii) neuroendocrine tumours (inc. Pancreatic, bronchial and intestinal carcinoid tumours) and (iii) rare gynaecological tumours (including but will not be limited to: vaginal or vulval carcinomas, clear cell carcinoma of the ovary, low grade serous ovarian cancer, mixed mullarian tumours (carcinosarcoma), sarcomas of the female genital tract and granulosa cell tumours). The role of immunotherapy is being defined in more common cancer types, however because of their rarity, the efficacy of immunotherapy for these cancers is poorly defined. This protocol provides an important opportunity to establish whether the combination of nivolumab & ipilimumab has efficacy in these cancers.